# Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.

> **NCT02153645** · PHASE3 · TERMINATED · sponsor: **Adamas Pharmaceuticals, Inc.** · enrollment: 87 (actual)

## Conditions studied

- Parkinson's Disease
- Levodopa Induced Dyskinesias (LID)

## Interventions

- **DRUG:** 240mg Amantadine HCl ER tablets
- **DRUG:** Placebo tablets
- **DRUG:** 320mg Amantadine HCl ER tablets

## Key facts

- **NCT ID:** NCT02153645
- **Lead sponsor:** Adamas Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-08-18
- **Primary completion:** 2016-05-20
- **Final completion:** 2016-05-20
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2022-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02153645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02153645, "Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02153645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*